Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bio 5 is a multi-strain probiotic dietary supplement developed and marketed by União Química under its Genom division in Brazil. It is formulated as an oral powder supplied in 4g sachets, with each sachet containing 20 billion active cultures across five specific probiotic strains: Bifidobacterium lactis BI-04, Bifidobacterium lactis BI-07, Bifidobacterium lactis HN019, Lactobacillus acidophilus NCFM, and Lactobacillus paracasei LPC-37. Bio 5 is designed to restore and maintain the healthy balance of both the intestinal and vaginal microbiota. It is primarily used to promote gastrointestinal health, alleviate digestive disorders (such as irritable bowel syndrome, chronic constipation, and antibiotic-associated diarrhea), support the immune system, and prevent recurrent urogenital infections (such as bacterial vaginosis and candidiasis) in women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bio 5.